Keyphrases
Adult Patients
100%
Enzyme Replacement Therapy
100%
Fabry Disease
100%
Management Recommendations
100%
Treatment Recommendations
100%
Therapy Initiation
50%
Natural History
25%
Adjunctive Therapy
25%
Pediatric Patients
25%
Clinical Practice Guidelines
25%
GLA Gene
25%
X-linked
25%
Comprehensive Evaluation
25%
Glycosphingolipids
25%
Disease Phenotype
25%
Adjuvant Therapy
25%
Personalized Approach
25%
Female Patients
25%
Clinical Benefit
25%
Cardiac Phenotype
25%
Multidisciplinary Team
25%
Response to Therapy
25%
β-Galactosidase (β-Gal)
25%
Pediatric Onset
25%
Lysosomal Storage Disease
25%
Monitoring Guidelines
25%
Life-threatening Complications
25%
X Chromosome Inactivation
25%
Late-onset
25%
Organ Damage
25%
Disease Manifestations
25%
Multiorgan Involvement
25%
Organ Involvement
25%
Routine Monitoring
25%
Classic Phenotype
25%
Non-classic
25%
Late Initiation
25%
Residual Enzyme Activity
25%
Therapy Treatment
25%
Medicine and Dentistry
Enzyme Replacement Therapy
100%
Fabry Disease
100%
Diseases
75%
Pediatrics Patient
25%
Pediatrics
25%
Glycosphingolipid
25%
Enzyme Activity
25%
Storage Disease
25%
Lysosomal Storage Disease
25%
Adjuvant Therapy
25%
X Chromosome Inactivation
25%
Galactosidase
25%
Pharmacology, Toxicology and Pharmaceutical Science
Replacement Therapy
100%
Fabry Disease
100%
Diseases
75%
Storage Disease
25%
Lysosome Storage Disease
25%
Glycosphingolipid
25%
Galactosidase
25%
Biochemistry, Genetics and Molecular Biology
Fabry Disease
100%
Enzyme
100%
X-Inactivation
25%
Enzyme Activity
25%
Glycosphingolipid
25%
Galactosidase
25%